Hengrui H1 2025 Financial ReportHengrui PharmaceuticalsHengrui Medicine’s 2025 half-year report shows 60% revenue from innovative drugs and $12B potential overseas deals, highlighting strong growth, R&D depth, and global expansion.
Hengrui Medicine, Head-to-Head Challenge with SemaglutideSemaglutideHengrui Pharmaceuticals is challenging semaglutide with its GLP-1R/GIPR dual agonist HRS9531 in a head-to-head clinical trial for type 2 diabetes. Early data from EASD 2024 shows significant HbA1c reduction, weight loss, and good tolerability, paving the way for further development.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
